NasdaqGM:RYTMBiotechs
What Rhythm Pharmaceuticals (RYTM)'s Strong IMCIVREE Revenue Beat Means For Shareholders
Rhythm Pharmaceuticals recently reported preliminary unaudited 2025 results showing IMCIVREE net product revenues of about US$57 million in the fourth quarter and US$194 million for the full year, both reflecting solid growth versus earlier periods.
An interesting aspect of this update is that roughly two-thirds of IMCIVREE revenue still comes from the U.S., underlining how central that market remains to Rhythm’s commercial story even as global sales expand.
We’ll now examine how this...